SCM
Suvretta Capital Management Portfolio holdings
AUM
$2.65B
This Quarter Return
+30.99%
1 Year Return
+18.59%
3 Year Return
+180.23%
5 Year Return
+278.12%
10 Year Return
+1,101.07%
AUM
$2.19B
AUM Growth
+$2.19B
(+18%)
Cap. Flow
-$50.9M
Cap. Flow
% of AUM
-2.33%
Top 10 Holdings %
Top 10 Hldgs %
47.59%
Holding
101
New
13
Increased
23
Reduced
21
Closed
13
Top Buys
| 1 |
Ultragenyx Pharmaceutical
RARE
|
$69.2M |
| 2 |
Goldman Sachs
GS
|
$42.6M |
| 3 |
TSMC
TSM
|
$40.4M |
| 4 |
Ferguson
FERG
|
$34M |
| 5 |
Apollo Global Management
APO
|
$32.5M |
Top Sells
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$91M |
| 2 |
Advanced Micro Devices
AMD
|
$53.5M |
| 3 |
Wynn Resorts
WYNN
|
$42.5M |
| 4 |
NVIDIA
NVDA
|
$38.5M |
| 5 |
Amazon
AMZN
|
$38.2M |
Sector Composition
| 1 | Healthcare | 68.4% |
| 2 | Technology | 8.43% |
| 3 | Consumer Discretionary | 6.04% |
| 4 | Communication Services | 5.73% |
| 5 | Industrials | 4.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Sana Biotechnology
SANA
$777M
| $6.55M | 0.3% |
1,606,056
-1,357,648
| -46% | -$5.54M |
|
52
Teva Pharmaceuticals
TEVA
$21.1B
| $5.19M | 0.23% |
497,400
| – | – |
|
53
AstraZeneca
AZN
$248B
| $4.75M | 0.21% |
70,490
| – | – |
|
54
Thermo Fisher Scientific
TMO
$186B
| $3.85M | 0.17% |
7,260
| – | – |
|
55
Danaher
DHR
$147B
| $3.8M | 0.17% |
16,427
| – | – |
|
56
Kenvue
KVUE
$39.7B
| $3.69M | 0.17% |
171,596
| – | – |
|
57
Abbott
ABT
$231B
| $3.69M | 0.17% |
33,520
+12,900
| +63% | +$1.42M |
|
58
Korro Bio
KRRO
$217M
| $3.54M | 0.16% |
+73,821
| New | +$3.54M |
|
59
Spyre Therapeutics
SYRE
$996M
| $3.49M | 0.16% |
162,395
| – | – |
|
60
PepGen
PEPG
$38M
| $3.31M | 0.15% |
486,611
| – | – |
|
61
Cencora
COR
$56.5B
| $2.56M | 0.12% |
12,488
| – | – |
|
62
Incyte
INCY
$16.5B
| $2.36M | 0.11% |
37,600
| – | – |
|
63
Galapagos
GLPG
$2.07B
| $1.92M | 0.09% |
47,200
| – | – |
|
64
Alnylam Pharmaceuticals
ALNY
$58.5B
| $1.89M | 0.09% |
+9,860
| New | +$1.89M |
|
|
AKLI
65
DELISTED
Akili, Inc. Common Stock
AKLI
| $1.87M | 0.08% |
3,841,718
| – | – |
|
66
Gilead Sciences
GILD
$140B
| $1.84M | 0.08% |
22,700
| – | – |
|
67
Merck
MRK
$210B
| $1.69M | 0.08% |
+15,500
| New | +$1.69M |
|
|
MOLN
68
Molecular Partners
MOLN
$140M
| $1.67M | 0.08% |
400,000
| – | – |
|
69
IQVIA
IQV
$32.4B
| $1.66M | 0.08% |
7,175
| – | – |
|
70
Natera
NTRA
$23.1B
| $1.54M | 0.07% |
24,600
-27,300
| -53% | -$1.71M |
|
71
Pfizer
PFE
$141B
| $1.45M | 0.07% |
+50,300
| New | +$1.45M |
|
72
Medtronic
MDT
$119B
| $1.44M | 0.07% |
17,460
| – | – |
|
73
CVS Health
CVS
$92.8B
| $1.36M | 0.06% |
17,170
| – | – |
|
74
Stryker
SYK
$150B
| $1.31M | 0.06% |
4,360
| – | – |
|
75
Illumina
ILMN
$15.8B
| $1.22M | 0.06% |
8,730
| – | – |
|